Screening for and Treatment of Polycystic Ovary Syndrome in Teenagers

Experimental Biology and Medicine

Volumn 229, Issue 5, 2004, Pages 369-377

  Salmi, Darren J ^a   Zisser, Howard C ^a   Jovanovic, Lois ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

Adolescents; Elevated testosterone; Hyperandrogenism; Hyperinsulinemia; Oligomenorrhea; Polycystic ovary syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHINESE DRUG; CHROMIUM; CLOMIFENE CITRATE; FLUTAMIDE; GLUCOSE; GONADOTROPIN; HIGH DENSITY LIPOPROTEIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TIANGUI FANG; UNCLASSIFIED DRUG;

ACNE; ADOLESCENT DISEASE; CARDIOVASCULAR DISEASE; DIET RESTRICTION; EARLY DIAGNOSIS; EXERCISE; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INFERTILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PHYSICAL DISEASE; PUBERTY; RISK ASSESSMENT; SELF CONCEPT; SELF ESTEEM; SHORT SURVEY; TREATMENT PLANNING;

FALLOPIA;

EID: 2142822894     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422900504     Document Type: Short Survey

References (84)

1. Kovacs G, Smith J. A Guide to the Polycystic Ovary: Its effects on health and fertility. Castle Hill Barns. UK: TFM Publishing, 2002.
2. Achard C. Thiers J. Le virilisme pilaire et son association à l'insuffisance glycolytique (diabète des femme à barbe). Bull Acad Natl Med 86:51-83, 1921.
3. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29:181-191, 1935.
4. Battaglia C, Regnani G, Mancini F, Iughetti L, Flamigni C, Venturoli S. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients. A pilot study. Hum Reprod 17:771-776, 2002.
5. Jahanfar S, Eden JA, Warren P, Seppala M, Nguyen TV. A twin study of polycystic ovary syndrome. Fertil Steril 63:478-486, 1995.
6. Legro RS, Driscoll D, Strauss JF III, Fox J, Dunaif A. Evidence for a genetic basis for hyperanchogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 95:14956-14960, 1998.
7. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenism in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2031-2036, 2003.
8. Bridges NA, Cooke A, Healy MJ, Hindmarsh PC, Brook CG. Standards for ovarian volume in childhood and puberty. Fertil Steril 60:456-460, 1993.
9. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol 174:1-5, 2002.
10. Holte, J. Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? J Endocrinol Invest 21:589-601, 1998.
11. Rajkhowa M, Talbot JA, Jones PW, Clayton RN. Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Clin Endocrinol 44:85-90, 1996.
12. Witchel SF, Trivedi RN, Kammerer C. Frequency of the T228A polymorphism in the SORBS1 gene in children with premature pubarche and in adolescent girls with hyperandrogenism. Fertil Steril 80:128-132, 2003.
13. Tomboc M, Witchel SF. Frequencies of the D85 and Y85 variants of UGT2B15 in children and adolescent with hyperandrogenism. J Pediatr Endocrinol Metab 16:719-726, 2003.
14. Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkowa M, White D, Franks S, Antilla L, Pettersson KS, Huhtaniemi IT. A new contributing factor to polycystic ovary syndrome: the genetic variant of lueteinizing hormone. J Clin Endocrinol Metab 84:1711-1715, 1999.
15. Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R, Tomer Y. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 78:1240-1243, 2002.
16. Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol 147:717-725, 2002.
17. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 78:569-576, 2002.
18. Wood JR, Nelson VL, Ho C, Jansen E, Wang CY, Urbanek M, McAllister JM, Mosselman S, Strauss JF III. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 278:26380-26390, 2003.
19. Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor 1 hypothesis. Fertil Steril 58:655-666, 1992.
20. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84:1897-1899, 1999.
21. Meirow D, Schenker JG. The link between female infertility and cancer: epidemiology and possible aetiologies. Hum Reprod Update 2:63-75, 1996.
22. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88(4. Pt 1):554-559, 1996.
23. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77:1095-1105, 2002.
24. Kidson W. Polycystic ovary syndrome: a new direction in treatment. Med J Aust 169:537-540, 1998.
25. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84:165-169, 1999.
26. Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 138:38-44, 2001.
27. Arslanian SA, Lewy SD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 86:66-71, 2001.
28. Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 82:3389-3394, 1997.
29. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2562-2568, 2003.
30. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vase Biol 15:821-826, 1995.
31. Macut D, Micic D, Cvijovic G, Sumarac M, Kendereski A, Zoric S, Pejkovic D. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS). J Pediatr Endocrinol Metab 14(Suppl 5):1353-1359 (discussion. 1365), 2001.
32. Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med 156:556-560, 2002.
33. Rasgon NL, Rao RC, Hwang S, Altshuler LL, Elman S, Zuckerbrow-Miller J, Korenman SG. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 74:299-304, 2003.
34. Barth JH, Catalan J, Cherry CA, Day A. Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res 37:615-619, 1993.
35. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women. Postgrad Med J 69(809):186-189, 1993.
36. Kitzinger C, Willmott J. "The thief of womanhood": women's experience of polycystic ovarian syndrome. Soc Sci Med 54:349-361, 2002.
37. Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol 16:33-37, 2003.
38. McCluskey S, Evans C, Lacey JH, Pearce JM, Jacobs H. Polycystic ovary syndrome and bulimia. Fertil Steril 55:287-291, 1991.
39. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, Eds. Polycystic Ovary Syndrome. Boston: Blackwell, pp377-384, 1992.
40. Lewis V. Polycystic ovary syndrome: a diagnostic challenge. Obstet Gynecol Clin North Am 28:1-20, 2001.
41. Apter D, Bützow T, Laughlin GA, Yen SSC. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 80:2966-2973, 1995.
42. Kent SC, Legro RS. Polycystic ovary syndrome in adolescents. Adolesc Med 13:73-88, 2002.
43. Herter LD, Magalhaes JA, Spritzer PM. Relevance of the determination of ovarian volume in adolescent girls with menstrual disorders. L Clin Ultrasound 24:243-248, 1996.
44. Dramusic V, Goh VH, Rajan U, Wong YC, Ratnam SS. Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. J Pediatr Adolesc Gynecol 10:124-132, 1997.
45. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril 76:326-331, 2001.
46. Garcia-Rudaz MC, Ropelato MG, Escobar ME, Veldhuis JD, Barontini M. Amplified and orderly growth hormone secretion characterizes lean adolescents with polycystic ovary syndrome. Eur J Endocrinol 147:207-216, 2002.
47. Richards GE, Cavallo A, Meyer WJ III, Prince MJ, Peters EJ, Stuart CA, Smith ER. Obesity, acanthosis nigricans, insulin resistance, and hyperandrogenemia: pediatric perspective and natural history. J Pediatr 107:893-897, 1985.
48. DeClue TJ, Shah SC, Marchese M, Malone JI. Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female. J Clin Endocrinol Metab 72:1308-1311, 1991.
49. Bilo L, Meo R, Valentino R, Di Carlo C, Striano S, Nappi C. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 86:2950-2956, 2001.
50. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 63:1185-1227, 2003.
51. Taponen S, Martikainen H, Jarvelin MR, Laitinen J, Pouta A, Hartikainen AL, Sovio U, McCarthy MI, Franks S, Ruokonen A. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab 88:141-147, 2003.
52. Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol 145:749-755, 2001.
53. Gulekli B, Turhan NO, Senoz S, Kukner S, Oral H, Gokmen O. Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: a comparative study. Gynecol Endocrinol 7:273-277, 1993.
54. Vetr M, Sobek A. Low dose spironolactone in the treatment of female hyperandrogenism and hirsutism. Acta Univ Palacki Olomuc Fac Med 135:55-57, 1993.
55. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:99-102, 1998.
56. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 27:705-721, 2000.
57. Creatsas G, Koliopoulos C, Mastorakos G. Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci 900:245-252, 2000.
58. Lloyd T, Lin HM, Matthews AE, Bentley CM, Legro RS. Oral contraceptive use by teenage women does not affect body composition. Obstet Gynecol 100:235-239, 2002.
59. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril 77:919-927, 2002.
60. Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, Hillhouse EW, Prelevic GM. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87:4496-4501, 2002.
61. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 10:2705-2712, 1995.
62. Apter, D. How possible is the prevention of polycystic ovary syndrome development in adolescent patients with early onset of hyperandrogenism. J Endocrinol Invest 21:613-617, 1998.
63. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Norman RJ. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:812-819, 2003.
64. Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res 35:86-91, 2003.
65. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovary syndrome. Gynecol Endocrinol 17:51-56, 2003.
66. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146, 2000.
67. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88:148-156, 2003.
68. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 75:310-315, 2001.
69. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87:1555-1559, 2002.
70. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Merformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 29:160-169, 2001.
71. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to nonnalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85:3526-3530, 2000.
72. Ibáñez L, de Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88:4720-4724, 2003.
73. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107(4):E55, 2001.
74. Loverro G, Lorusso F, De Pergola G, Nicolardi V, Mei L, Selvaggi L. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 16:217-224, 2002.
75. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:4649-4654, 2003.
76. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79:562-566, 2003.
77. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 18: 1210-1218, 2003.
78. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 18:1618-1625, 2003.
79. Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 13(Suppl 5):1295-1298, 2000.
80. Hou J, Yu J, Wei M. Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang." Zhongguo Zhong Xi Yi Jie He Za Zhi 20:589-592, 2000.
81. Anderson RA. Chromium, glucose tolerance, and diabetes. Biol Trace Elem Res 32: 19-24, 1992.
82. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46:1786-1791, 1997.
83. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile, and insulin levels. Fertil Steril 79:1008-1014, 2003.
84. Yildirim M, Noyan V, Bulent Tiras M, Yildiz A, Guner H. Ovarian wedge resection by minilaparatomy in infertile patients with polycystic ovarian syndrome: a new technique. Eur J Obstet Gynecol Reprod Biol 107:85-87, 2003.